StockData
AbbVie Inc. logo

AbbVie Inc. (ABBV) operating KPIs

ABBVNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 3, 2026Score 10/3094% above fair value
$294.89+4.10 (+1.41%)

Close on Oct 30, 2026Market cap $521.11BP/E 83.3Yield 2.26%

AbbVie viekira (ombitasvir/paritaprevir/ritonavir) [legacy through FY20Q1] — Worldwide net revenues ($M) ($M)

Form 10-Q / 10-K Segment & Revenue Disaggregation Note & Form 8-K Key Product Revenues

Latest, Q4 2019
4
Period ended Dec 31, 2019
Change on a year earlier
-90.7%
43 in Q4 2018
History
10 quarters
Since Q3 2017
Sources
5
Documents cited below

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedViekira (ombitasvir/paritaprevir/ritonavir) [legacy through FY20Q1] — Worldwide net revenues ($M) ($M)Year on yearSource
Q4 2019Dec 31, 20194-90.7%Form 10-K (filed 2020-02-21) ↗
Q3 2019Sep 30, 20193-87.0%Form 10-Q (filed 2019-11-06) ↗
Q2 2019Jun 30, 20194-90.2%Form 10-Q (filed 2019-08-05) ↗
Q1 2019Mar 31, 201925-64.8%Form 10-Q (filed 2019-05-03) ↗
Q4 2018Dec 31, 201843-62.6%Form 10-K (filed 2020-02-21) ↗
Q3 2018Sep 30, 201823-87.3%Form 10-Q (filed 2019-11-06) ↗
Q2 2018Jun 30, 201841–Form 10-Q (filed 2019-08-05) ↗
Q1 2018Mar 31, 201871–Form 10-Q (filed 2019-05-03) ↗
Q4 2017Dec 31, 2017115–Form 10-K (filed 2020-02-21) ↗
Q3 2017Sep 30, 2017181–Form 10-Q (filed 2018-11-07) ↗

Breakdown

What makes up viekira (ombitasvir/paritaprevir/ritonavir) [legacy through fy20q1] — worldwide net revenues ($m)

Cite this data

StockData. (2026). AbbVie Viekira (ombitasvir/paritaprevir/ritonavir) [legacy through FY20Q1] — Worldwide net revenues ($M) ($M), quarterly Q3 2017–Q4 2019 [Data set]. Compiled from AbbVie SEC filings and investor materials. https://stockdatahq.com/stocks/abbv/kpis/viekira_ww

See every metric in the AbbVie KPI table. Data updated Oct 26, 2026.